Cormorant Asset Management, LP Gossamer Bio, Inc. Transaction History

Cormorant Asset Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$7.21 - $14.88 $21.6 Million - $44.6 Million	3,000,000 Added 1512.23%	3,198,382 $38.3 Million
Q2 2021 Aug 16, 2021	SELL	$8.0 - $9.75 $5.2 Million - $6.34 Million	-650,000 Reduced 76.62%	198,382 $1.61 Million
Q4 2020 Feb 16, 2021	BUY	$8.3 - $13.59 $4.98 Million - $8.15 Million	600,000 Added 241.56%	848,382 $8.2 Million
Q3 2020 Nov 16, 2020	SELL	$11.3 - $14.75 $1.14 Million - $1.49 Million	-100,943 Reduced 28.9%	248,382 $3.08 Million
Q2 2020 Aug 14, 2020	BUY	$9.52 - $15.98 $1.44 Million - $2.41 Million	150,943 Added 76.09%	349,325 $4.54 Million
Q1 2020 May 15, 2020	SELL	$8.0 - $15.48 $812,944 - $1.57 Million	-101,618 Reduced 33.87%	198,382 $2.01 Million
Q4 2019 Feb 14, 2020	SELL	$14.82 - $26.79 $4.71 Million - $8.52 Million	-318,129 Reduced 51.47%	300,000 $4.69 Million
Q3 2019 Nov 14, 2019	SELL	$16.02 - $22.47 $400,500 - $561,750	-25,000 Reduced 3.89%	618,129 $10.4 Million
Q2 2019 Aug 14, 2019	SELL	$16.12 - $22.89 $161,200 - $228,900	-10,000 Reduced 1.53%	643,129 $14.3 Million
Q1 2019 May 15, 2019	BUY	$17.58 - $23.97 $11.5 Million - $15.7 Million	653,129 New	653,129 $14.2 Million

108

167M

430K

519K

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $80.8M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.